Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Zavante Therapeutics

Request full access

Injectable antibiotic for multi-drug resistant bacterial infections

San Diego, United StatesFounded 2015Biotech & Life Sciences

About Zavante Therapeutics

Zavante Therapeutics, Inc. was a privately-held, late clinical-stage biopharmaceutical company founded in 2015 in San Diego, California. The company focused on developing and commercializing novel antibacterial agents to treat serious infections, particularly those caused by multi-drug resistant (MDR) pathogens in hospitalized patients.

The company's lead product candidate was an intravenous formulation of fosfomycin, initially known as ZTI-01 and later branded as ZOLYD™ and CONTEPO™. This first-in-class epoxide antibiotic was developed to provide a new treatment option for complicated urinary tract infections (cUTIs), including acute pyelonephritis, and other serious infections caused by MDR Gram-negative and Gram-positive bacteria. The intravenous version of fosfomycin, which has been used outside the U.S. for over 40 years, was repurposed by Zavante with a new dosing approach to optimize its effectiveness for the U.S. market. The FDA granted the drug Qualified Infectious Disease Product (QIDP) and Fast Track designations.

The company was founded by Ted Schroeder, who also served as President and CEO. Prior to Zavante, Schroeder co-founded Cadence Pharmaceuticals, where he also served as President and CEO until its acquisition in 2014. In July 2018, Zavante Therapeutics was acquired by Nabriva Therapeutics plc in a stock deal. The acquisition was valued at approximately $27 million upfront, with former Zavante stockholders eligible for up to $97.5 million in additional payments based on regulatory and commercial milestones. Following the acquisition, Ted Schroeder was appointed CEO of Nabriva Therapeutics.

Source: Dealroom company data

At a glance

Status
Acquired
Open positions
None listed
Dealroom signal
52.8/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Research and Development, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Jul 2018 $0 — Nabriva Therapeutics —
DEBTDebt Sep 2016 $10M — Square 1 Bank —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Zavante Therapeutics website traffic

Latest recorded traffic for Zavante Therapeutics is 10 monthly website visits, down 98.3% over the last three months.

Latest monthly visits10 3-month web change-98.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Origo BiopharmaPharmaceutical company focused on the research and development of novel therapeutic products that modulate the immune system San Cibrao das Viñas, Spain Acquired — $2.5M $10M
LIfT BioSciencesLift Biosciences is a rapidly emerging biotech company bringing to market a first-in-class allogeneic innate cell therapy London, United Kingdom Operational
Jiangsu Dingtai Pharmaceutical ResearchOffering disease model and pharmacodynamics research, drug policy and safety assessment, and clinical and laboratory services, along with a high-quality laboratory animal supply system Nanjing City, China Operational
Bio PaletteBio Palette aims to become a world-leading company in the field of microbiome therapeutics by using bacteria optimized by genome editing to modify and control microbiomes Kobe, Japan Operational
ASYLIACompanion Diagnostics For Immunotherapy | Asylia Diagnostics Beerse, Belgium Operational
RoukenBioRedefines drug discovery with personalized in vitro services and partnerships from early research to GMP-ready assays Newarthill, United Kingdom Low Activity
SoProsFocus on the potential of microalgae, especially the useful ingredients of labyrinthula auranthiochytrium, in the healthcare business Tsukuba, Japan Operational
Abarceo PharmaDeveloping small molecule technology platform for the treatment of mitochondrial dysfunction, with an initial focus on T2D Malmö kommun, Sweden Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Zavante Therapeutics in the San Diego ecosystem

Live from Dealroom

The Zavante Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Square 1 Bank
  • Frazier Healthcare Partners
  • Longitude Capital

Other known investors1 additional known investor

  • Nabriva Therapeutics
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Zavante Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Zavante Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.